EP0986552A1 - 5-naphtalen-1-yl-1,3-dioxane derivate,deren herstellung und deren verwendung alsheilmittel - Google Patents

5-naphtalen-1-yl-1,3-dioxane derivate,deren herstellung und deren verwendung alsheilmittel

Info

Publication number
EP0986552A1
EP0986552A1 EP98928419A EP98928419A EP0986552A1 EP 0986552 A1 EP0986552 A1 EP 0986552A1 EP 98928419 A EP98928419 A EP 98928419A EP 98928419 A EP98928419 A EP 98928419A EP 0986552 A1 EP0986552 A1 EP 0986552A1
Authority
EP
European Patent Office
Prior art keywords
group
general formula
mmol
mixture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98928419A
Other languages
English (en)
French (fr)
Inventor
Gihad Dargazanli
Patrick Lardenois
Jonathan Frost
Pascal George
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9706944A external-priority patent/FR2764287B1/fr
Priority claimed from FR9706947A external-priority patent/FR2764291B1/fr
Priority claimed from FR9706946A external-priority patent/FR2764289B1/fr
Priority claimed from FR9706945A external-priority patent/FR2764288B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of EP0986552A1 publication Critical patent/EP0986552A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • R x represents an alkyl group
  • V represents a hydrogen atom or a linear or branched alkyl group, cycloalkyl, cycloalkylmethyl, phenylalkyl optionally substituted on the phenyl ring, carboxymethyl, alkoxycarbonylmethyl, carbamoylmethyl optionally monosubstituted or disubstituted on nitrogen
  • W represents a carboxymethyl group, alkoxycarbonylmethyl optionally monosubstitutes or disubstitutes on nitrogen, a cyclic group having from 4 to 7 vertices and optionally containing an oxygen or sulfur atom, a pyridin-2-ylmethyl group, a pyridin-3-ylmethyl group, a pyridin group 4-ylmethyl, an 1-methylpyrrol-2-ylmethyl group, a furan-2-ylmethyl group, a thien-2-ylmethyl group or a 1, 3-thiazol-2-ylmethyl group, or alternatively
  • V and W together form, and with the nitrogen atom which carries them, a pyrrolidinyl, piperidinyl or 1,2,3,4-tetrahydroisoquinoline group.
  • the compounds of the invention more particularly correspond to one of the general formulas (IA), (IB), (IC) and (ID)
  • R x represents a hydrogen atom or a linear or branched (C 2 -C 4 ) alkyl group, (C 3 -C 6 ) cycloalkyl, (C 3 -C 6 ) cycloalkylmethyl or phenyl ( ⁇ 3 ) alkyl optionally substituted on the phenyl ring,
  • R 2 represents a hydrogen atom or a (C 1 -C 4 ) linear or branched alkyl group, (C 3 -C 6 ) cycloalkyl, (C 3 -C 6 ) cycloalkylmethyl or phenyl (C 1 -C 3 ) alkyl optionally substituted on the phenyl ring
  • R 3 represents a hydroxy group or (C- L -C) alkoxy or a group of general formula NR 4 R 5 in which R and R 5 , independently of one another, each represent a hydrogen atom, a (C- L -C ⁇ linear or branched alkyl group, a (C 3 -C 5 ) cycloalkyl group or a (C 3 -C 6 ) cycloalkylmethyl group.
  • the compounds of general formula (IA) can exist in the form of cis or trans stereoisomers or mixtures of such isomers; they may also exist in the form of free bases or of addition salts with acids.
  • the compounds of general formula (IA) can be prepared by various methods described below.
  • the amide of formula (IIA) is subjected to a dealkylation in the presence of sodium sulfide, in a polar aprotic solvent, for example N-methylpyrrolidone, at a temperature of 100 to 150 ° C, to obtain the amide of formula (IIIA), according to a method described in J. Am. Chem. Soc. (1976) 98 3237.
  • a polar aprotic solvent for example N-methylpyrrolidone
  • the latter is then hydrolyzed in a basic medium, for example sodium hydroxide, in a protic solvent, for example water or an aliphatic alcohol, at a temperature of 25 to 100 ° C., to obtain the corresponding primary amine, then it is treated the latter either with an aldehyde of general formula
  • R 6 -CH0 in which R 6 is the lower homolog of group R 2 , in the presence of a reducing agent such as sodium borohydride or sodium cyanoborohydride, under reductive amination conditions known to man of career, to obtain an amine of general formula (VA).
  • a reducing agent such as sodium borohydride or sodium cyanoborohydride
  • the amine of general formula (VA) is then reacted with ethyl bromoacetate, to obtain a compound of general formula (IA) in which R 1 and R 2 represent an alkyl, cycloalkyl, cycloalkylalkyl or phenylalkyl group and R 3 represents an ethoxy group.
  • the compound thus obtained can then be saponified to transform it into the corresponding acid, or it can be reacted with an amine of general formula HNR 4 R 5 , in which R 4 and R 5 are such as defined above, to transform it into an amide.
  • the conditions for these reactions are conventional and are well known to those skilled in the art.
  • the amines of general formula (VA) can be prepared in which R x represents a cyclopropylmethyl group and R 2 represents an alkyl or phenylalkyl group either by reduction of the corresponding alkanamides, described in patent application EP-461958, or by hydrolysis into primary amine of said alkanamides, then by treatment of these amines under N-monoalkylation conditions. All these reactions are carried out according to methods well known to those skilled in the art.
  • a compound of general formula (IA) can be prepared in which R 1 represents a hydrogen atom by demethylation, using sodium sulphide in N, N-dimethylformamide, of the corresponding compound, in the formula of which R represents a methyl group, described in patent application FR-2742152.
  • the dash "-” is part of the name, and the dash “_” is only used for breaking at the end of the line; it must be deleted in the absence of a break, and must not be replaced either by a normal dash or by a space.
  • Example IA Compound No. 2A.
  • 0.23 ml (2.6 mmol) of cyclopropylmethanamine, 20 ml of dioxane and 0.36 ml of triethylamine are introduced into a 250 ml flask, a solution of 0.21 ml (2, 6 mmol) of chloroacetyl chloride in 5 ml of dioxane, and the mixture is stirred at room temperature for 8 h. 30 ml of water, 1 g of potassium carbonate and 1.0 g (2.7 mmol) of 5- [6- (cyclopropylmethoxy) naphthalen-1-yl] - N-ethyl - 1, 3-dioxane are added.
  • Example 2A (Compound ⁇ ° 3A). N-Cyclopropyl -2 - [[3- [5- [6- (cyclopropylmethoxy) naphthalen-1- yl] -1, 3-dioxan-2-yl] propyl] ethylamino] acetamide.
  • aqueous phase is concentrated under reduced pressure, the residue is taken up with ethanol, which again provides 1.22 g of white solid, ie a total of 1.92 g of compound which is used as it is in the next step.
  • 0.69 g (1.87 mmol) of 5- [6- (cyclopropylmethoxy) naphthalen-1-yl] -N-ethyl - 1,3-dioxane-2-propanamine in solution is introduced into a 100 ml flask. 20 ml of acetonitrile, 0.37 g (2.77 mmol) of 2-chloro-N-cyclopropylacetamide and 0.26 g of potassium carbonate, and the mixture is heated at 70 ° C. for 4 hours.
  • Example 3A (Compound No. 17A). 2- [[3- [5- [6- (Cyclopropylmethoxy) naphthalen-1-yl] -1, 3-dioxan-2- yl] propyl] methylamino] -N- (cyclopropylmethyl) acetamide.
  • the solvent is evaporated under reduced pressure, the residue is taken up in toluene and it is evaporated under reduced pressure, and the residue is dried.
  • 0.24 ml (2.81 mmol) of cyclopropanemethanamine, 20 ml of dioxane, and 0.4 ml of triethylamine are introduced into a 250 ml flask, and a solution of 0.22 ml is added dropwise ( 2.81 mmol) of chloroacetyl chloride) in 10 ml of dioxane, and the mixture is stirred at room temperature for 9 h. 30 ml of water, 1 g of potassium carbonate and 1 g (2.81 mmol) of 5- [6- (cyclopropylmethoxy) naphthalen-1-yl] -N- methyl-1,3-dioxane-2 are added.
  • Example 4A (Compound ⁇ ° 19A).
  • the organic phases are combined, washed with water and then with saturated sodium chloride solution and dried over magnesium sulfate.
  • the solvent is filtered and evaporated under reduced pressure, and the residue is purified by chromatography on a column of silica gel, eluting with a 98/2 mixture of dichloromethane and methanol.
  • 4.5 g (13.7 mmol) of N- [3- [5- (6-hydroxynaphthalen-1-yl) -1, 3-dioxan-2-yl] propyl] are introduced into a 250 ml flask acetamide dissolved in 70 ml of N, N-dimethylformamide, 2.8 g of potassium carbonate and 1.53 ml (20.5 mmol) of bromoethane, and the mixture is stirred at room temperature overnight.
  • the hydrochloride is prepared from a 0.1N solution of hydrochloric acid in propan-2-ol. Melting point: 180-183 ° C.
  • the solvent is evaporated off under reduced pressure, the white residue is taken up with water and ethyl acetate, the organic phase is washed twice with water and once with ethyl acetate, dried over magnesium sulfate, filtered, the solvent is evaporated off under reduced pressure, and the residual oil is purified by chromatography on a column of silica gel, eluting with a 95/5 mixture of dichloromethane and methanol.
  • the mixture is allowed to cool, water and ethyl acetate are added, the organic phase is separated, the aqueous phase is extracted once more, the organic phase is washed twice with water and once with a saturated aqueous solution of sodium chloride, it is dried over magnesium sulphate, it is filtered, the solvent is evaporated under reduced pressure, and the residue is purified by chromatography on a column of silica gel, eluting with a 99 / 1 of dichloromethane and methanol.
  • Example 5A (Compound No. 20A). 2- [[3- [5- (6-Ethoxynaphthalen-1-yl) -1, 3-dioxan-2-yl] propyl] _ (phenylmethyl) amino] -N-methylacetamide.
  • the solvent is evaporated off under reduced pressure, and
  • Example 6A (Compound No. 23A). 2- [[3- [5- [6- (Cyclopentyloxy) naphthalen-1-yl] -1, 3-dioxan-2yl] propyl] (phenylmethyl) amino] acetamide.
  • N- [3- [5- [(6-Phenylmethoxy) naphthalen-1-yl] -1, 3-dioxan-2-yl] propyl] acetamide From 4.2 g (12.75 mmol) of N- [3- [5- (6-hydroxy_ naphthalen-1-yl) -1, 3-dioxan-2-yl] propyl] acetamide and 1.82 ml (15.3 mmol) of (bromomethyl) benzene, and operating under conditions analogous to those described in Example 4A.2, 4.67 g of product are obtained, of which 0.3 g is recrystallized from a mixture 6 / 4 ethanol and water, to obtain 0.15 g of white solid. Melting point: 138-140 ° C.
  • cC 3 H 5 represents a cyclopropyl group
  • cC 5 H 9 represents a cyclopentyl group
  • C 6 H 5 represents a phenyl group.
  • R represents either a hydrogen atom or a group of general formula CH 2 C0Y in which Y represents a hydroxy group or a (C 1 -C 4 ) alkoxy group, or also a group of general formula C ⁇ CONR ⁇ in wherein R x and R 2 , independently of each other, each represent a hydrogen atom or a (C- L -C, ⁇ ) alkyl group,
  • X represents an oxygen or sulfur atom or a CH 2 group
  • m represents 0 or 1
  • n 0, 1 or 2.
  • the compounds of general formula (IB) can exist in the form of cis or trans stereoisomers or mixtures of such isomers; on the other hand, certain compounds, due to the chirality of the cycle linked to the nitrogen atom, can exist in the form of diastereoisomers and / or enantiomers. They can also exist in the form of free bases or of addition salts with acids.
  • the compounds of general formula (IB) can be prepared by a process illustrated by scheme B which follows.
  • the 2- (6-methoxynaphthalen-1-yl) propane-1, 3-diol of formula (IIB) is reacted with 4, 4-diethoxybutanamine of formula (IIIB) at reflux of a non-protic solvent such as toluene and in the presence of dry hydrochloric acid in solution in diethyl ether as catalyst to obtain 5- (6-methoxynaphthalen-1-yl) -1, 3-dioxan-2-propanamine of formula (IVB), then reacts the latter with a ketone of general formula (VB), in which X, m and n are as defined above, in the presence of a reducing agent such as sodium borohydride or any other equivalent agent, in the medium neutral or acid, under reducing amination conditions well known to those skilled in the art.
  • a compound of general formula (IBa) is obtained which corresponds to the general formula (IB) when
  • the compound of general formula (IBb) can then be reacted with an amine of general formula HNR X R 2 , in which R x and R 2 are as defined above, to obtain an amide of general formula (IBc).
  • the conditions for this reaction are conventional and are well known to those skilled in the art.
  • An amide of general formula (IBc) can also be obtained directly from a compound of general formula (IBa) by alkylation with a halide of general formula Z-CH 2 -CO-NR- L R 2 , in which Z represents a chlorine or bromine atom and R ⁇ and R 2 are as defined above, in a polar aprotic solvent, for example N, N-dimethylformamide, in the presence of a base, for example of potassium carbonate.
  • a polar aprotic solvent for example N, N-dimethylformamide
  • the mixture is cooled, 2 g of sodium borohydride are added, the mixture is stirred for 1 h, 100 ml of water are added, the mixture is extracted four times with 75 ml of ethyl acetate, the solvent is evaporated under pressure reduced and the residue is dried under reduced pressure.
  • hydrochloride is prepared using 5 ml of a 0.1 M solution of hydrochloric acid in propan-2-ol. After washing with diisopropyl ether and drying, 0.08 g of hydrochloride is obtained. Melting point: 172-173 ° C.
  • HCl means a hydrochloride; the acid: base molar ratio is indicated in parentheses.
  • R- L represents either a hydrogen atom or a group of general formula CH 2 C0Y in which Y represents a hydroxy group or a (C 1 -C 4 ) alkoxy group, or also a group of general formula CH 2 CONR 4 R 5 in which R 4 and R 5 , independently of each other, each represent a hydrogen atom or a (C 1 -C 4 ) alkyl group, and
  • R 2 represents a pyridin-2-yl group, a pyridin-3-yl group, a pyridin-4-yl group, an l-methylpyrrol-2-yl group, a furan-2-yl group, a thien-2 group -yle or a group 1, 3-thiazol-2-yl, the respective formulas of which are as follows:
  • the compounds of general formula (IC) can exist in the form of cis or trans stereoisomers or mixtures of such isomers; they may also exist in the form of free bases or of addition salts with acids.
  • a compound of general formula (ICa) is obtained which corresponds to the general formula (IC) when R represents a hydrogen atom.
  • the latter can be saponified under conditions well known to those skilled in the art to obtain a compound of general formula (ICb) in which Y represents a hydroxy group.
  • the general formula (ICb) corresponds to the general formula (IC) when R x represents a group of general formula CH 2 C0Y.
  • the compound of general formula (ICb) can then be reacted with an amine of general formula HNR 4 R 5 , in which R 4 and R 5 are as defined above, to obtain an amide of general formula (ICc).
  • the conditions for this reaction are conventional and are well known to those skilled in the art.
  • An amide of general formula (ICc) can also be obtained directly from a compound of general formula (ICa) by alkylation using a halide of general formula Z-CH 2 -CO-NR 4 R 5 , in which Z represents a chlorine or bromine atom and R 4 and R 5 are as defined above in an aprotic polar solvent, for example N, N-dimethylformamide, in the presence of a base, for example potassium carbonate.
  • aprotic polar solvent for example N, N-dimethylformamide
  • the general formula (ICc) corresponds to the general formula (IC) when R x represents a group of general formula CH 2 CONR 4 R 5
  • Example 2C (Compound No. 3C). 2- [[3- [5- (6-methoxynaphthalen-1-yl) -1, 3-dioxan-2-yl] propyl] (pyridin-4-ylmethyl) amino] acetamide dihydrochloride
  • the mixture is allowed to cool, 140 ml of water are added and the mixture is extracted with four times 50 ml of ethyl acetate. After evaporation of the solvent under reduced pressure, the residue is purified by chromatography on a column of silica gel, eluting with a 9/1 mixture of dichloromethane and methanol, and 0.3 g of pure base is obtained.
  • the base is salified by means of 8 ml of 0.1 N solution of hydrochloric acid in propan-2-ol. After washing with ethyl acetate and drying, 0.17 g of dihydrochloride is obtained.
  • Example 3C (Compound No. 19C). 5- (6-methoxynaphthalen-1-yl) -N- (thiazol-2-ylmethyl) -1,3-dioxan-2-propanamine hydrochloride.
  • the methanol is evaporated under reduced pressure, the residue is taken up with water and ethyl acetate, the organic phase is separated, washed and dried over magnesium sulfate, and the solvent is evaporated off reduced pressure.
  • C 5 H 4 N-2- represents a pyridin-2-yl group
  • C 5 H 4 N-3- represents a pyridin-3-yl group
  • C 5 H 4 N-4- represents a pyridin-4-yl group
  • CH 3 -lC 4 H 3 N-2- represents a l-methylpyrrol-2-yl group
  • C 4 H 3 0-2- represents a furan-2-yl group
  • C 4 H 3 S-2- represents a thien-2-yl group
  • C 3 H 2 NS-2- represents a 1, 3-thiazol-2-yl group.
  • Y represents a hydroxy group, a (C 1 -C 4 ) alkoxy group, or a group of general formula NR 4 R 5 in which R 4 and R 5 , independently of one another, each represent an atom of hydrogen or a (C 1 -C 4 ) alkyl group, and
  • R- L and R 2 form, with the nitrogen atom and the carbon atom which connect them, a pyrrolidine cycle, a piperidine cycle or a 1,2,3,4-tetrahydroisoquinoline cycle.
  • the compounds of general formula (ID) can exist in the form of cis or trans stereoisomers or mixtures of such isomers; moreover, and because of the asymmetric carbon atom in ⁇ of the group -C (0) Y, they can exist in the form of pure enantiomers or mixtures of enantiomers. They can also exist in the form of free bases or of addition salts with acids.
  • the 2- (6-methoxynaphthalen-1-yl) propane-1,3-diol of formula (IID) is reacted with 2- (3-chloropropyl) -1, 3-dioxolane of formula (IIID), in the medium acid and in an aprotic solvent, to obtain 2- (3-chloropropyl) -5- (6-methoxynaphthalen-1-yl) -1, 3-dioxolane of formula (IVD), and finally the latter is reacted with a amine of general formula (VD), in which Y, R and R 2 are as defined above, in the presence of an organic or inorganic base, in an aprotic solvent, for example N, N-dimethylformamide, at a temperature from 20 to 110 ° C.
  • aprotic solvent for example N, N-dimethylformamide
  • Example 2D (Compound N ° 2D). 1- [3- [5- (6-Methoxynaphthalen-1-yl) -1, 3-dioxan-2-yl] propyl] -L- prolinamide.
  • Example 3D (Compound ⁇ ° 6D). 2- [3- [5- (6-methoxynaphthalen-1-yl) -1,3-dioxan-2-yl] propyl] -N-methyl oxalate - 1,2,3,4-tetrahydroisoquinoline-3-carbox_ amide.
  • the compounds according to the invention have been the subject of pharmacological tests which have demonstrated their interest as therapeutic substances.
  • the entry of calcium caused by a depolarizing stimulus into the cortical synaptosomes of the rat can be measured using a fluorescent probe, according to the method described by A. Deffois et al. in Neurosciences Letters (1996) 220 117-120.
  • a sodium channel agonist such as veratridine (10 ⁇ M)
  • IC 50 concentration inhibiting the response by 50%
  • the results are expressed by the DA 50 , a dose which protects 50% of the animals, calculated according to the method of JT Lichtfield and F. Wilcoxon [J. Pharm. Exp. Ther. , 96, 99-113 (1949)), using the Probit TM software, from 3 or 4 doses each administered to a group of 8 mice.
  • the DA 50 of the most active compounds range from 1 to 10 mg / kg.
  • the compounds were subjected to the global cerebral ischemia test in mice.
  • the ischemia is due to cardiac arrest induced by a rapid intravenous injection of magnesium chloride.
  • the "survival time” that is to say the interval between the time of injection of magnesium chloride and the last observable respiratory movement of each mouse. This last movement is considered the ultimate index of a function of the central nervous system.
  • Respiratory arrest occurs approximately 19 seconds after the injection of magnesium chloride.
  • Male mice (Charles River CD1) are studied in groups of 10. They are fed and watered ad libitum before the tests. The survival time is measured 10 minutes after the intraperitoneal administration of the compounds of the invention.
  • the results are given in the form of the difference between the survival time measured in a group of 10 mice having received the compound and the survival time measured in a group of 10 mice having received the carrier liquid.
  • the relationships between the modifications in the survival term and the dose of the compound are recorded graphically according to a semilogarithmic curve.
  • This curve allows the calculation of the "effective dose 3 seconds" (DE 3 .J, that is to say the dose (in mg / kg) which produces a 3 second increase in survival time compared to the control group. of 10 untreated mice. An increase in survival time of 3 seconds is both statistically significant and reproducible.
  • the ED 3 habof the most active compounds of the invention are of the order of 0.05 to 0.2 mg / kg intravenously.
  • the antinociceptive activity is evaluated in the rat, during the second phase of a formal test adapted from the work of Tjolsen A., Berge O.-G., Hunskaar S., Rosland J. H. and
  • Formalin (5%) is injected subcutaneously (100 ⁇ l) into the arch of the left hind paw.
  • the nociception is quantified, after injection, by the measurement, for the injected paw, of the total duration of licks, between +20 and +35 min, and by the number of tremors, measured by sequences of 2 min, every 5 min , between +35 and +60 min.
  • the compounds are administered at doses of 30 and 60 mg / kg, in suspension (water + 1% Tween 80), orally (5 ml / kg), 30 min before the formalin injection.
  • the activity threshold for the compounds of the invention corresponds to reductions of 35 to 40%. The most active compounds cause a reduction of 50% at a dose of 30 mg / kg orally.
  • the results of the tests show that the compounds according to the invention have neuroprotective properties, and that they can therefore be used for the preparation of medicaments useful in the treatment or prevention of cerebrovascular disorders of ischemic or hypoxic origin (infarction). cerebral, cranial or medullary trauma, cardiac or respiratory arrest, transient ischemic attack, perinatal asphyxia), glaucoma, progressive neurodegenerative diseases (senile dementias such as Alzheimer's disease, vascular dementias, Parkinson's disease, Huntington's disease, olivo-ponto-cerebellar atrophy, amyotrophic lateral sclerosis, neurodegenerative diseases of viral origin, etc.) and in the prevention of ischemic strokes associated with cardiac and vascular surgery and endovascular therapy.
  • the compounds of the invention can be presented in all forms of pharmaceutical compositions suitable for enteral or parenteral administration, such as tablets, dragees, capsules, suspensions or oral or injectable solutions such as syrups, ampoules, etc., associated with suitable excipients, and dosed to allow daily administration of 1 to 1000 mg of active substance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
EP98928419A 1997-06-05 1998-06-03 5-naphtalen-1-yl-1,3-dioxane derivate,deren herstellung und deren verwendung alsheilmittel Withdrawn EP0986552A1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
FR9706944A FR2764287B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
FR9706944 1997-06-05
FR9706947A FR2764291B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706946 1997-06-05
FR9706946A FR2764289B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706945 1997-06-05
FR9706945A FR2764288B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706947 1997-06-05
PCT/FR1998/001113 WO1998055474A1 (fr) 1997-06-05 1998-06-03 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
EP0986552A1 true EP0986552A1 (de) 2000-03-22

Family

ID=27447000

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98928419A Withdrawn EP0986552A1 (de) 1997-06-05 1998-06-03 5-naphtalen-1-yl-1,3-dioxane derivate,deren herstellung und deren verwendung alsheilmittel

Country Status (18)

Country Link
EP (1) EP0986552A1 (de)
JP (1) JP2002502412A (de)
KR (1) KR20010013435A (de)
CN (1) CN1265658A (de)
AR (1) AR012908A1 (de)
AU (1) AU8025198A (de)
BG (1) BG103937A (de)
BR (1) BR9810742A (de)
CA (1) CA2290695A1 (de)
CO (1) CO4940480A1 (de)
EE (1) EE9900560A (de)
HU (1) HUP0002166A3 (de)
IL (1) IL133242A0 (de)
NO (1) NO995966L (de)
PL (1) PL337234A1 (de)
SK (1) SK166199A3 (de)
TR (1) TR199903022T2 (de)
WO (1) WO1998055474A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007822A2 (en) * 2000-07-21 2002-01-31 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69103968T2 (de) * 1990-06-15 1995-03-23 Synthelabo 2-(Aminoalkyl)-5-(arylalkyl)1,3-dioxanderivate, ihre Herstellung und ihre Anwendung in der Therapeutik.
FR2714055B1 (fr) * 1993-12-22 1996-01-19 Synthelabo Dérivés de 5-(arylalkyl)-1,3-dioxane substitués en position 2, leur préparation et leur utilisation en thérapeutique.
FR2742152B1 (fr) * 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9855474A1 *

Also Published As

Publication number Publication date
AR012908A1 (es) 2000-11-22
BG103937A (en) 2000-07-31
HUP0002166A3 (en) 2002-12-28
CA2290695A1 (en) 1998-12-10
CN1265658A (zh) 2000-09-06
SK166199A3 (en) 2000-06-12
BR9810742A (pt) 2000-09-12
NO995966D0 (no) 1999-12-03
NO995966L (no) 2000-02-04
EE9900560A (et) 2000-06-15
TR199903022T2 (xx) 2000-04-21
HUP0002166A2 (hu) 2001-06-28
CO4940480A1 (es) 2000-07-24
IL133242A0 (en) 2001-03-19
JP2002502412A (ja) 2002-01-22
KR20010013435A (ko) 2001-02-26
PL337234A1 (en) 2000-08-14
AU8025198A (en) 1998-12-21
WO1998055474A1 (fr) 1998-12-10

Similar Documents

Publication Publication Date Title
EP1499589B1 (de) N-¬phenyl(piperidin-2-yl)methyl|benzamidderivate,verfahren zu ihrer herstellung und ihre therapeutische anwendung
EP0202164B1 (de) (Benzoyl-4-piperidino)-2-phenyl-1-alkanolderivate, ihre Herstellung und ihre Verwendung als Heilmittel
EP0428437A1 (de) 1,2-Benzisoxazolderivate, Verfahren zu deren Herstellung, und sie enthaltende pharmazeutische Zusammensetzungen
OA13317A (fr) Dérivés de N-hétérocyclylméthylbenzamides, leur préparation et leur application en thérapeutique.
EP0042781B1 (de) 1-(4- Chinolyl), 2- oder 3- (2- oder 3-piperidyl oder pyrrolidinyl)-Äthanon oder -Propanon, Verfahren zu seiner Herstellung und seine Anwendung als Arzneimittel
WO2004013101A2 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
CA2542727A1 (fr) Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide, et n-[[azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
CH644348A5 (fr) Amino-ethers oxydes, leur procede de preparation et medicament les contenant.
EP0306375A1 (de) 2-[(4-Piperidinyl)methyl]-1,2,3,4-tetrahydrochinolin-Derivate, ihre Herstellung und ihre therapeutische Verwendung
CA2565293C (fr) Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique
EP0524846A1 (de) 2-(Piperidin-1-yl)ethanolderivate, ihre Herstellung und ihre Anwendung in der Therapie
FR2706895A1 (en) Tetrahydroisoquinoline derivatives, their preparation and their application in therapeutics
EP0929550A1 (de) N-(benzothiazol-2-yl)piperidine-1-ethanamine derivate, ihre herstellung und therapeutische verwendung
FR2713641A1 (fr) Dérivés de l'épi-épibatidine.
JPH01186866A (ja) 分割化アミノピロリジン神経防護剤
WO1998055474A1 (fr) Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
KR100437561B1 (ko) 신규헤테로고리화합물
EP0035925B1 (de) 3-Chlorchinolinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP0869952B1 (de) Derivate von 5-naphthalin-1-yl-1,3-dioxanen, ihre herstellung und therapeutische anwendung
EP0534856B1 (de) Thienocyclopentanonoximether, ihre Herstellung und diese enthaltende Arzneimittel
EP0351283A1 (de) 2-[(4-Piperidinyl)methyl]-2,3-dihydro-1H-isoindol- und 2,3,4,5-tetrahydro-1H-benzazepin-Derivate, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
FR2688504A1 (fr) Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique.
FR2714055A1 (fr) Dérivés de 5-(arylalkyl)-1,3-dioxane substitués en position 2, leur préparation et leur utilisation en thérapeutique.
FR2764287A1 (fr) Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
EP2313392A1 (de) Polysubstituierte azetidinverbindungen, deren herstellung und deren therapeutische anwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000105;LT PAYMENT 20000105;LV PAYMENT 20000105;MK PAYMENT 20000105;RO PAYMENT 20000105;SI PAYMENT 20000105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010822